Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01037218 · ClinicalTrials.gov registry record · Phase 3
Treatment of Erectile Dysfunction II
A Phase 3 study of Erectile Dysfunction, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 601
- Enrollment target
- 20
- Study locations
NCT01037218 is a Phase 3 study of Erectile Dysfunction that has completed, run by Warner Chilcott. The registered enrollment target is 601 participants, above the 213-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (182% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT01037218, a Phase 3 study of Erectile Dysfunction, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 601 participants
- Enrollment target
- 20
- Study locations
Study Summary
Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Udenafil
Study Locations (20)
Florida
- Warner Chilcott Investigational Site - Aventura
- Warner Chilcott Investigational Site - Daytona Beach
- Warner Chilcott Investigational Site - DeLand
- Warner Chilcott Investigational Site - Ocala
- Warner Chilcott Investigational Site - Tampa
Alabama
- Warner Chilcott Investigational Site - Birmingham
- Warner Chilcott Investigational Site - Huntsville
California
- Warner Chilcott Investigational Site - Chino
- Warner Chilcott Investigational Site - Tarzana
Georgia
- Warner Chilcott Investigational Site - Dawsonville
- Warner Chilcott Investigational Site - Sandy Springs
Indiana
- Warner Chilcott Investigational Site - Fort Wayne
- Warner Chilcott Investigational Site - Greenwood
Maryland
- Warner Chilcott Investigational Site - Elkridge
- Warner Chilcott Investigational Site - Greenbelt
Arizona
- Warner Chilcott Investigational Site - Tempe
Colorado
- Warner Chilcott Investigational Site - Englewood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 601 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01037218
The ClinicalTrials.gov registry entry for NCT01037218 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 601 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 213-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (182% higher). The listed sponsor is Warner Chilcott, which has 53 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Erectile Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01037218 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Alabama, California.
Frequently Asked Questions
What is clinical trial NCT01037218 about?
NCT01037218 is a clinical study titled "Treatment of Erectile Dysfunction II". Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).
What is the current status of trial NCT01037218?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 601 participants. The study started on 2009-09. Estimated completion is 2010-04.
What conditions does trial NCT01037218 study?
This clinical trial studies the following conditions: Erectile Dysfunction.
What interventions are being tested in trial NCT01037218?
The interventions under investigation include: Placebo (DRUG), Udenafil (DRUG).
Who is sponsoring clinical trial NCT01037218?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01037218 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erectile Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Actual Use Trial of Tadalafil 5 mg
RECRUITING · Phase 3
-
Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement
ACTIVE NOT RECRUITING · Phase 3
-
An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms
COMPLETED · Phase 3
-
Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer
COMPLETED · Phase 3
-
Study to Investigate the Efficacy and Safety of Vardenafil Flexible Dose Versus Placebo in Males With Erectile Dysfunction
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.